Fujifilm Pharmaceuticals U.S.A., Inc.
Subsidiary of Fujifilm Holdings Corporation (4901) · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | ribonucleotide reductase / DNA polymerase (dCTP competition)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
May 2029 (1)
Est. primary completion 2029-05 · NCT05318573 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.